Effect of intravenous gamma globulin on short- and mid-term clinical outcome in acute viral myocarditis in children


Acute viral myocarditis is an extremely diverse disease with a predictable good outcome with supportive therapy. The objective of this study was to look at the clinical outcome of patients receiving additional intravenous gamma globulin compared to those receiving conventional anti-congestive therapy alone. Patients and methods: This is a retrospective review of charts of children admitted with acute myocarditis. Group 1 was children who received intravenous gamma globulin (IVIG) along with conventional anti-congestive therapy. Group 2 were patients who received the conventional anticongestive therapy alone. Short-term outcome was survival to hospital discharge, and mid-term outcome was improvement of left ventricular ejection fraction at 6 months and one year follow-up. Results: A total of 36 patients were enrolled and 18 were males. The mean age of all patients was 2.3 ± 2.6 years and the mean duration of illness for the whole group was 6.7 ± 3.8 days. Group 1 comprised of 16 patients. There was no difference in short-term outcome with mortality of 2 patients in Group1 (12.5%) and 3(15%) in Group 2 (p = 0.2). At intermediate term follow up, recovery of ejection fraction in Group 1 was in 4/14 (28%) and in Group 2 it was 9/17 (55%) and at 12 months it was 10/13 (77%) in Group 1 and 15/16 (94%) in Group 2 (p = 0.02 and 0.19 respectively). Conclusion: Acute myocarditis has a high spontaneous cure rate. Our study did not show any significant difference in the short-term or midterm outcome between children receiving IVIG compared to those who did not.

Share and Cite:

Atiq, M. , Hoda, M. and Aslam, N. (2014) Effect of intravenous gamma globulin on short- and mid-term clinical outcome in acute viral myocarditis in children. World Journal of Cardiovascular Diseases, 4, 39-44. doi: 10.4236/wjcd.2014.42007.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Kim, H.J., Yoo, G.H. and Kil, H.R. (2010) Clinical outcome of acute myocarditis in children ccording to treatment modalities. Korean Journal of Pediatrics, 53, 745-752.
[2] Blauwet, L.A. and Cooper, L.T. (2010) Myocarditis. Progress in Cardiovascular Diseases, 52, 274-288.
[3] D’Ambrosio, A., Patti, G., Manzoli, A., Sinagra, G., Di Lenarda, A., Silvestri, F. and Di Sciascio, D. (2001) The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: A review. Heart, 85, 499-504.
[4] Drucker, N.A., Colan, S.D., Lewis, A.B., Beiser, A.S., Wessel, D.L., Takahashi, M., Baker, A.L., Perez-Atayde, A.R. and Newburger, J.W. (1994) Gammaglobulin treatment of acute myocarditis in the pediatric population. Circulation, 89, 252-257.
[5] Frustaci, A., Chimenti, C., Calabrese, F., et al. (2003) Immunosuppressive therapy for active lymphocytic myocarditis: Virological and immunologic profile of responders versus nonresponders. Circulation, 107, 857-863.
[6] Haque, A., Bhatti, S. and Siddiqui, F.J. (2009) Intravenous immune globulin for severe acute myocarditis in children. Indian Pediatr, 46, 810-811.
[7] Kim, H.S., Sohn, S., Park, J.Y. and Seo, J.W. (2004) Fulminant myocarditis successfully treated with high dose immunoglobulin. International Journal of Cardiology, 96, 485-486.
[8] Klugman, D., Berger, J.T., Sable, C.A., He, J., Khandewal, S.G. and Slonim, A.D. (2010) Pediatric patients hospitalized with myocarditis: A multi-institutional analysis. Pediatric Cardiology, 31, 222-228.
[9] Takeda, Y., Yasuda, S., Miyazaki, S., Daikoku, S., Nakatani, S. and Nonogi, H. (1998) High-dose immunoglobulin G therapy for fulminant myocarditis. Japanese Circulation Society, 62, 871-872.
[10] Kendirli, T., Nacar, N., Ciftci, E., Belgemen, T., Ince, E., Atalay, S. and Tutar, E. (2003) Cardiac Troponin I in acute myocarditis treated with a 12-hour infusion of high dose intravenous immunoglobulin. J Ankara Med School, 25, 89-94.
[11] Parrillo, J.E. (2001) Inflammatory cardiomyopathy (Myocarditis): Which patients should be treated with anti-inflammatory therapy? Circulation, 104, 4-6.
[12] Batra, A.S. and Lewis, A.B. (2001) Acute myocarditis. Current Opinion in Pediatrics, 13, 234-239.
[13] Levi, D. and Alejos, J. (2001) Diagnosis and treatment of pediatric viral myocarditis. Current Opinion in Cardiology, 16, 77-83.
[14] Tang, W.H.W. and Ooi, H.H. (2010) Myocarditis: Current treatment overview. Journal of Cardiac Failure, 16, E176-E179.
[15] McCarthy, R.E., Boehmer, J.P., Hruban, R.H., Hutchins, G.M., Kasper, E.K., Hare, J.M. and Baughman, K.L. (2000) Long-Term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. The New England Journal of Medicine, 342, 690-695.
[16] Morgera, T., Di Lenarda, A., Dreas, L., et al. (1992) Electrocardiography of myocarditis revisited: Clinical and prognostic significance of electrocardiographic changes. American Heart Journal, 124, 433-467.
[17] Schultz, J.C., Hilliard, A.A., Cooper Jr., L.T. and Rihal, C.S. (2009) Diagnosis and treatment of viral myocarditis. Mayo Clinic Proceedings, 84, 1001-1009.
[18] Vashist, S. and Singh, G.K. (2009) Acute myocarditis in children: Current concepts and management. Current Treatment Options in Cardiovascular Medicine, 1, 383-391.
[19] Burch, M. (2004) Immune suppressive treatment in paediatric myocarditis: Still awaiting the evidence. Heart, 90, 1103-1104.
[20] Fuse, K., Kodama, M., Okura, Y., Ito, M., Hirono, S., Kato, K., Hanawa, H. and Aizawa, Y. (2000) Predictors of disease course in patients with acute myocarditis. Circulation, 102, 2829-2835.
[21] Hufnagel, G., Pankuweit, S., Richter, A., Schonian, U. and Maisch, B. (2000) The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results. Herz, 25, 279-285.
[22] Durani, Y., Egan, M., Baffa, J., et al. (2009) Pediatric myocarditis: Presenting clinical characteristics. The American Journal of Emergency Medicine, 27, 942-947.
[23] Felker, G.M., Boehmet, J.P., Hruban, R.H., Hutchins, G.M., Kasper, E.K., Baughman, K.L. and Hare, J.M. (2000) Echocardiographic findings in fulminant acute myocarditis. Journal of the American College of Cardiology, 36, 227-232.
[24] Mendes, L.A., Dec, G.W., Picard, M.H., Palacios, I.F., Newell, J. and Davidoff, R. (1994) Right ventricular dysfunction: An independent predictor of outcome in patients with myocarditis. American Heart Journal, 128, 301-307.
[25] McNamara, D.M., Holubkov, R., Starling, R.C., Dec, G.W., Loh, E., Torre-Amione, G., et al. (2001) Controlled trial of intravenous immune globulin in recentonset dilated cardiomyopathy. Circulation, 103, 2254-2259.
[26] McNamara, D.M., Starling, R.C., Dec, G.W., et al. (1999) Intervention in myocarditis and acute cardiomyopathy with immune globulin: Results from the randomized placebo controlled IMAC trial. Circulation, 100, I-21.
[27] Lee, C.H., Tsai, W.C., Hsu, C.H., Liu, P.Y., Lin, L.J. and Chen, J.H. (2006) Predictive factors of a fulminant course in acute myocarditis. International Journal of Cardiology, 109, 142-145.
[28] Magnani, J.W. and Dec, G.W. (2006) Myocarditis: Current trends in diagnosis and treatment. Circulation, 113, 876-890. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.584532
[29] Wheeler, D.S. and Kooy, N.W. (2003) A formidable challenge: The diagnosis and treatment of viral myocarditis in children. Critical Care Clinics, 19, 365-391.
[30] Tsai, Y.G., Ou, T.Y., Wang, C.C., Tsai, M.C., Yuh, Y.S. and Hwang, B. (2001) Intravenous gammaglobulin therapy in myocarditis complicated with complete heart block: Report of one case. Acta Paediatr Taiwan, 42, 311-313.
[31] Robinson, J., Hartling, L., Vandermeer, B., Crumley, E. and Klassen, T.P. (2005) Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane Database of Systematic Reviews, 25, Article ID: CD004370.
[32] English, R.F., Janosky, J.E., Ettedgui, J.A. and Webber, S.A. (2004) Outcomes for children with acute myocarditis. Cardiology in the Young, 14, 488-493.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.